To evaluate the dynamics and prognostic value of immune checkpoints PD-1, PD-L1, and PD-L2 in HMA treatment cycles, a total of 135 patients with intermediate/high-risk MDS were enrolled and retrospectively investigated in this present study. The gene discussed is CD274; the disease is myelodysplastic syndrome.